These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Prognostic impact of diffuse large B-cell lymphoma subgroups in patients undergoing autologous SCT.
    Author: Hallack Neto AE, Dulley FL, Coelho Siqueira SA, Pracchia LF, Belesso M, Saboya R, Sturaro D, Amigo-Filho JU, Mendrone Junior A, Chamone DA, Pereira J.
    Journal: Bone Marrow Transplant; 2009 Feb; 43(4):323-5. PubMed ID: 18850022.
    Abstract:
    A total of 53 patients aged 18-60 years with high-intermediate or high-risk diffuse large B-cell lymphoma (DLBCL) were evaluated to analyze the impact of the cell of origin. Of 53 patients, 16 underwent autologous SCT (ASCT) in first remission and the rest received conventional chemotherapy. Immunohistochemistry was evaluated in 47 cases: 17 were of germinal center (GC) origin and 30 were of non-GC origin. There was no survival difference between the two groups. Overall survival (OS) and disease-free survival (DFS) at 3 years were 93 and 83%, respectively, for the 14 patients who underwent ASCT. Their DFS was significantly better than that of patients who achieved CR but did not undergo ASCT. We conclude that ASCT is safe and improves the DFS of high-intermediate and high-risk DLBCL, regardless of the cell of origin. This observation should be confirmed in a larger study.
    [Abstract] [Full Text] [Related] [New Search]